Laurus Labs Q1FY27: stock jumps 53%, results in focus

Q1FY27 rally puts Laurus Labs back in the spotlight

Laurus Labs shares recorded a sharp move in the April to June 2026 quarter (Q1FY27), rising 53% and marking the stock’s strongest quarterly rally in five years. During the period, the share price also hit a record high of ₹1,530.30 on the BSE. On Tuesday at 02:28 PM, the stock was quoted 1% higher at ₹1,518, while the BSE Sensex was broadly flat at 76,730.

The recent run-up follows a phase where the company delivered positive returns of over 10% in each of the past three months. The comparison point in the company’s own history is Q1FY22, when the stock rose 88% during the quarter. The latest price action has renewed attention on earnings visibility, segment mix, and the trajectory of the contract manufacturing business.

Where the stock stands on price, market cap and valuation

Market snapshots in the provided data show Laurus Labs around ₹1,450-₹1,454, with different market-cap readings cited in the same context. One data point lists a market cap of about ₹71,455 crore alongside a P/E of 80.4. Another market snapshot shows a market cap of ₹78,560 crore at a current price of ₹1,454, with a 52-week high/low range of ₹1,493 / ₹663.

The company is also described as showing a “moderate growth signal” based on ranking data. While such signals are not financial results, they often reflect a blend of price momentum and fundamentals in screening models.

FY26 performance: revenue growth and margin expansion

In FY26, Laurus Labs reported revenue of ₹6,813 crore, up 23% over the previous year. The growth was attributed mainly to significant expansion in the CDMO business, supported by the Affordable Medicine portfolio (Generics). The company’s gross margin was described as healthy and maintained around the 60% range.

Profitability improved meaningfully during FY26. EBITDA margins expanded by 6.7 percentage points to 26.8% for the full year. The information also highlights that Q4 EBITDA margin reached nearly 29%, and that margins are expected to be maintained or improved in FY27.

CDMO mix and the FY2030 target

A key part of the Laurus Labs narrative is the increasing contribution from contract development and manufacturing. The company expects continued strong growth next year with its order book “well in place,” according to Soumya Chava.

The CDMO segment is also central to the longer-term mix change: CDMO revenues are projected to reach 50% of overall sales by FY2030. Investors have been tracking this shift because it can change the company’s revenue stability, customer concentration risk, and margin profile over time.

Q1 expectations for FY27: estimates versus base numbers

For Q1FY27, Uniresearch estimates point to revenue of ₹2,063 crore, up 31.4% year-on-year, and profit after tax (PAT) of ₹243 crore, up 50.0% year-on-year. The same context cites Q1FY26 as the base period with revenue of ₹1,570 crore and PAT of ₹162 crore.

The Q1 results date for FY27 was described as not yet officially announced in the provided material. Typically, such dates are communicated through a board meeting notice filed on NSE or BSE portals after the quarter ends.

What the last reported quarter snapshot showed on margins and segments

The data also contains a detailed quarter snapshot with operational metrics that help frame what investors might watch in upcoming results. It cites revenue of ₹1,570 crore, gross margin of 59%, EBITDA of ₹389 crore with a margin of 25%, and net profit of ₹163 crore (net margin 13%).

Segment detail in the same snapshot lists CDMO revenue at ₹493 crore and Generics revenue at ₹1,048 crore. R&D spend is cited at 4.3% of sales, or ₹68 crore. Capital expenditure for the quarter is listed at ₹265 crore, while net debt is cited at ₹2,388 crore with a debt-to-EBITDA ratio of 1.8%.

Capacity expansion plans and regulatory execution points

In the provided narrative, Laurus Labs is described as announcing three capacity expansions: a microbial fermentation initiative, a facility for gene therapy and antibody-drug conjugates, and a finished formulation plant. These additions were positioned as potential growth opportunities linked to demand in both CDMO and generics.

Another operational datapoint highlighted is that Laurus Labs “successfully completed 39 quality audits without any critical observations,” underlining its compliance posture in a regulated industry. A separate note adds that Laurus Bio, in the large molecule CDMO space, recorded Q1 sales of ₹29 crore and was described as stagnant year-on-year due to scaling challenges.

Andhra Pradesh land allotment and planned investment

The text also references a state-led infrastructure development angle. The Government of Andhra Pradesh allotted 531.77 acres near Visakhapatnam in IP Rambilli Phase-II of Anakapalli District for establishing the Laurus Pharma Zone (LPZ). The company projected an investment of ₹5,630 crore and employment for 6,350 people in three phases over eight years.

Such projects are typically watched for timelines, capital intensity, and eventual output ramp-up, especially when the company is also balancing capex with leverage metrics like net debt and debt-to-EBITDA.

Management commentary: execution, pipeline and facility buildout

In the quoted management comments, Founder and CEO Satyanarayana Chava said the company made “healthy progress” to start the year with increasing contributions from CDMO and continued advancement of pipeline projects, supported by Generic FDF. He also pointed to a focus on “commercial execution” and scaling technology capabilities.

The CEO added that construction had commenced on facilities across CDMO, Generics and FDF, and that these would strengthen the company’s ability to operate as a development and manufacturing partner at scale, including in advanced therapies. The company reiterated confidence in its strategic direction and longer-term value creation.

Market impact: what investors are reacting to

The immediate market trigger in the provided information is the magnitude of the Q1FY27 price move, including a record high and the sharpest quarterly rally in five years. The fundamental backdrop includes FY26 revenue growth of 23% to ₹6,813 crore, and margin expansion with FY26 EBITDA margin at 26.8% and Q4 nearing 29%.

The narrative around CDMO is central to investor positioning. The stated target of CDMO reaching 50% of sales by FY2030, plus management commentary that the order book is “well in place,” supports the market’s focus on visibility rather than one-off quarterly beats.

Conclusion

Laurus Labs entered Q1FY27 with a 53% quarterly share-price rise and a fresh record high, as investors weighed FY26 growth and improving margins against a CDMO-led medium-term story. Near-term attention is likely to remain on the official Q1FY27 results date and whether the company sustains momentum in CDMO revenues and margins in FY27.